http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 01 Oct 2026 08:10:11 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/ZYUS+reports+Phase+2a+trial+results+for+non-opioid+cancer+pain+drug/27131950.html <p>ZYUS Life Sciences Corporation (TSXV: ZYUS) reported topline results from its Phase 2a UTOPIA-1 clinical trial evaluating Trichomylin® softgel capsules in patients with advanced cancer experiencing moderate to severe cancer-related pain, according to a press release issued Oct. 1, 2026.</p> <p>The trial enrolled 11 patients across three Canadian sites — McGill University Health Center, CancerCare Manitoba, and Centre Hospitalier de l'Université de Montreal. All patients were maintained on standard-of-care pain management, including long-acting opioids, throughout the trial. Of the 11 enrolled, 91% successfully titrated to an individualized, stable dose, and no treatment-related serious adverse events were observed.</p> <p>In a subset of seven http://www.streetinsider.com/FDA/ZYUS+reports+Phase+2a+trial+results+for+non-opioid+cancer+pain+drug/27131950.html Thu, 01 Oct 2026 08:10:11 -0400 ZYUS http://www.streetinsider.com/Press+Releases/ZYUS+Life+Sciences+Announces+Positive+Topline+Results+from+Phase+2a+UTOPIA-1+Trial+Evaluating+Novel+Non-Opioid+Pain+Drug+in+Patients+with+Advanced+Cancer/27131948.html <div class="xn-content"> <ul type="disc"> <li>Phase 2a UTOPIA-1 trial results showed Trichomylin® softgel capsules demonstrated clinically relevant efficacy signals using multiple pain assessments.</li> <li>Trichomylin® softgel capsules were well-tolerated, with no related serious adverse events observed, supporting the sustainability of an individualized titration dosing regimen.</li> http://www.streetinsider.com/Press+Releases/ZYUS+Life+Sciences+Announces+Positive+Topline+Results+from+Phase+2a+UTOPIA-1+Trial+Evaluating+Novel+Non-Opioid+Pain+Drug+in+Patients+with+Advanced+Cancer/27131948.html Thu, 01 Oct 2026 08:09:00 -0400 ZYUS http://www.streetinsider.com/PRNewswire/ZYUS+Life+Sciences+Announces+Positive+Topline+Results+from+Phase+2a+UTOPIA-1+Trial+Evaluating+Novel+Non-Opioid+Pain+Drug+in+Patients+with+Advanced+Cancer/27131948.html <div class="xn-content"> <ul type="disc"> <li>Phase 2a UTOPIA-1 trial results showed Trichomylin® softgel capsules demonstrated clinically relevant efficacy signals using multiple pain assessments.</li> <li>Trichomylin® softgel capsules were well-tolerated, with no related serious adverse events observed, supporting the sustainability of an individualized titration dosing regimen.</li> http://www.streetinsider.com/PRNewswire/ZYUS+Life+Sciences+Announces+Positive+Topline+Results+from+Phase+2a+UTOPIA-1+Trial+Evaluating+Novel+Non-Opioid+Pain+Drug+in+Patients+with+Advanced+Cancer/27131948.html Thu, 01 Oct 2026 08:09:00 -0400 ZYUS http://www.streetinsider.com/Press+Releases/ZYUS+Life+Sciences+Expands+U.S.+Patent+Portfolio+with+Second+Pain+Management+Patent/26436802.html <div class="xn-content"> <p class="prntac"><i>Issuance of <location value="LC/us" idsrc="xmltag.org" >U.S.</location> patent supports ongoing clinical research in chronic and neuropathic pain </i></p><p><span class="legendSpanClass"><location value="LU/ca.sk.sasoon" idsrc="xmltag.org" >SASKATOON, SK</location></span>, <span class="legendSpanClass"><chron>May 5, 2026</chron></span> /PRNewswire/ - <span value="TorontoVE:ZYUS" idsrc="xmltag.org" >ZYUS Life Sciences Corporation</span> (the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, announced today that the United States Patent and Trademark Office ("USPTO") has issued <location value="LC/us" idsrc="xmltag.org" >U.S.</location> Patent No. 12,616,704, entitled CANNABICHROMENE FORMULATION FOR PAIN MANAGEMENT on today's date.  The patent, held by ZYUS' wholly owned subsidiary, <span>ZYUS Life Sciences http://www.streetinsider.com/Press+Releases/ZYUS+Life+Sciences+Expands+U.S.+Patent+Portfolio+with+Second+Pain+Management+Patent/26436802.html Tue, 05 May 2026 18:00:00 -0400 A.06822034 O.02548881 O.20026344 ZYUS http://www.streetinsider.com/PRNewswire/ZYUS+Life+Sciences+Expands+U.S.+Patent+Portfolio+with+Second+Pain+Management+Patent/26436802.html <div class="xn-content"> <p class="prntac"><i>Issuance of <location value="LC/us" idsrc="xmltag.org" >U.S.</location> patent supports ongoing clinical research in chronic and neuropathic pain </i></p><p><span class="legendSpanClass"><location value="LU/ca.sk.sasoon" idsrc="xmltag.org" >SASKATOON, SK</location></span>, <span class="legendSpanClass"><chron>May 5, 2026</chron></span> /PRNewswire/ - <span value="TorontoVE:ZYUS" idsrc="xmltag.org" >ZYUS Life Sciences Corporation</span> (the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, announced today that the United States Patent and Trademark Office ("USPTO") has issued <location value="LC/us" idsrc="xmltag.org" >U.S.</location> Patent No. 12,616,704, entitled CANNABICHROMENE FORMULATION FOR PAIN MANAGEMENT on today's date.  The patent, held by ZYUS' wholly owned subsidiary, <span>ZYUS Life Sciences http://www.streetinsider.com/PRNewswire/ZYUS+Life+Sciences+Expands+U.S.+Patent+Portfolio+with+Second+Pain+Management+Patent/26436802.html Tue, 05 May 2026 18:00:00 -0400 A.06822034 O.02548881 O.20026344 ZYUS http://www.streetinsider.com/Press+Releases/ZYUS+Life+Sciences+Expands+U.S.+Patent+Portfolio+with+Second+Pain+Management+Patent/26436802.html <div class="xn-content"> <p class="prntac"><i>Issuance of <location value="LC/us" idsrc="xmltag.org" >U.S.</location> patent supports ongoing clinical research in chronic and neuropathic pain </i></p><p><span class="legendSpanClass"><location value="LU/ca.sk.sasoon" idsrc="xmltag.org" >SASKATOON, SK</location></span>, <span class="legendSpanClass"><chron>May 5, 2026</chron></span> /PRNewswire/ - <span value="TorontoVE:ZYUS" idsrc="xmltag.org" >ZYUS Life Sciences Corporation</span> (the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, announced today that the United States Patent and Trademark Office ("USPTO") has issued <location value="LC/us" idsrc="xmltag.org" >U.S.</location> Patent No. 12,616,704, entitled CANNABICHROMENE FORMULATION FOR PAIN MANAGEMENT on today's date.  The patent, held by ZYUS' wholly owned subsidiary, <span>ZYUS Life Sciences http://www.streetinsider.com/Press+Releases/ZYUS+Life+Sciences+Expands+U.S.+Patent+Portfolio+with+Second+Pain+Management+Patent/26436802.html Tue, 05 May 2026 18:00:00 -0400 A.06822034 O.02548881 O.20026344 ZYUS http://www.streetinsider.com/PRNewswire/ZYUS+Life+Sciences+Expands+U.S.+Patent+Portfolio+with+Second+Pain+Management+Patent/26436802.html <div class="xn-content"> <p class="prntac"><i>Issuance of <location value="LC/us" idsrc="xmltag.org" >U.S.</location> patent supports ongoing clinical research in chronic and neuropathic pain </i></p><p><span class="legendSpanClass"><location value="LU/ca.sk.sasoon" idsrc="xmltag.org" >SASKATOON, SK</location></span>, <span class="legendSpanClass"><chron>May 5, 2026</chron></span> /PRNewswire/ - <span value="TorontoVE:ZYUS" idsrc="xmltag.org" >ZYUS Life Sciences Corporation</span> (the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, announced today that the United States Patent and Trademark Office ("USPTO") has issued <location value="LC/us" idsrc="xmltag.org" >U.S.</location> Patent No. 12,616,704, entitled CANNABICHROMENE FORMULATION FOR PAIN MANAGEMENT on today's date.  The patent, held by ZYUS' wholly owned subsidiary, <span>ZYUS Life Sciences http://www.streetinsider.com/PRNewswire/ZYUS+Life+Sciences+Expands+U.S.+Patent+Portfolio+with+Second+Pain+Management+Patent/26436802.html Tue, 05 May 2026 18:00:00 -0400 A.06822034 O.02548881 O.20026344 ZYUS http://www.streetinsider.com/Press+Releases/ZYUS+Life+Sciences+Expands+U.S.+Patent+Portfolio+with+Second+Pain+Management+Patent/26436802.html <div class="xn-content"> <p class="prntac"><i>Issuance of <location value="LC/us" idsrc="xmltag.org" >U.S.</location> patent supports ongoing clinical research in chronic and neuropathic pain </i></p><p><span class="legendSpanClass"><location value="LU/ca.sk.sasoon" idsrc="xmltag.org" >SASKATOON, SK</location></span>, <span class="legendSpanClass"><chron>May 5, 2026</chron></span> /PRNewswire/ - <span value="TorontoVE:ZYUS" idsrc="xmltag.org" >ZYUS Life Sciences Corporation</span> (the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, announced today that the United States Patent and Trademark Office ("USPTO") has issued <location value="LC/us" idsrc="xmltag.org" >U.S.</location> Patent No. 12,616,704, entitled CANNABICHROMENE FORMULATION FOR PAIN MANAGEMENT on today's date.  The patent, held by ZYUS' wholly owned subsidiary, <span>ZYUS Life Sciences http://www.streetinsider.com/Press+Releases/ZYUS+Life+Sciences+Expands+U.S.+Patent+Portfolio+with+Second+Pain+Management+Patent/26436802.html Tue, 05 May 2026 18:00:00 -0400 A.06822034 O.02548881 O.20026344 ZYUS http://www.streetinsider.com/PRNewswire/ZYUS+Life+Sciences+Expands+U.S.+Patent+Portfolio+with+Second+Pain+Management+Patent/26436802.html <div class="xn-content"> <p class="prntac"><i>Issuance of <location value="LC/us" idsrc="xmltag.org" >U.S.</location> patent supports ongoing clinical research in chronic and neuropathic pain </i></p><p><span class="legendSpanClass"><location value="LU/ca.sk.sasoon" idsrc="xmltag.org" >SASKATOON, SK</location></span>, <span class="legendSpanClass"><chron>May 5, 2026</chron></span> /PRNewswire/ - <span value="TorontoVE:ZYUS" idsrc="xmltag.org" >ZYUS Life Sciences Corporation</span> (the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, announced today that the United States Patent and Trademark Office ("USPTO") has issued <location value="LC/us" idsrc="xmltag.org" >U.S.</location> Patent No. 12,616,704, entitled CANNABICHROMENE FORMULATION FOR PAIN MANAGEMENT on today's date.  The patent, held by ZYUS' wholly owned subsidiary, <span>ZYUS Life Sciences http://www.streetinsider.com/PRNewswire/ZYUS+Life+Sciences+Expands+U.S.+Patent+Portfolio+with+Second+Pain+Management+Patent/26436802.html Tue, 05 May 2026 18:00:00 -0400 A.06822034 O.02548881 O.20026344 ZYUS http://www.streetinsider.com/Press+Releases/ZYUS+Life+Sciences+Expands+U.S.+Patent+Portfolio+with+Second+Pain+Management+Patent/26436802.html <div class="xn-content"> <p class="prntac"><i>Issuance of <location value="LC/us" idsrc="xmltag.org" >U.S.</location> patent supports ongoing clinical research in chronic and neuropathic pain </i></p><p><span class="legendSpanClass"><location value="LU/ca.sk.sasoon" idsrc="xmltag.org" >SASKATOON, SK</location></span>, <span class="legendSpanClass"><chron>May 5, 2026</chron></span> /PRNewswire/ - <span value="TorontoVE:ZYUS" idsrc="xmltag.org" >ZYUS Life Sciences Corporation</span> (the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, announced today that the United States Patent and Trademark Office ("USPTO") has issued <location value="LC/us" idsrc="xmltag.org" >U.S.</location> Patent No. 12,616,704, entitled CANNABICHROMENE FORMULATION FOR PAIN MANAGEMENT on today's date.  The patent, held by ZYUS' wholly owned subsidiary, <span>ZYUS Life Sciences http://www.streetinsider.com/Press+Releases/ZYUS+Life+Sciences+Expands+U.S.+Patent+Portfolio+with+Second+Pain+Management+Patent/26436802.html Tue, 05 May 2026 18:00:00 -0400 A.06822034 O.02548881 O.20026344 ZYUS http://www.streetinsider.com/PRNewswire/ZYUS+Life+Sciences+Expands+U.S.+Patent+Portfolio+with+Second+Pain+Management+Patent/26436802.html <div class="xn-content"> <p class="prntac"><i>Issuance of <location value="LC/us" idsrc="xmltag.org" >U.S.</location> patent supports ongoing clinical research in chronic and neuropathic pain </i></p><p><span class="legendSpanClass"><location value="LU/ca.sk.sasoon" idsrc="xmltag.org" >SASKATOON, SK</location></span>, <span class="legendSpanClass"><chron>May 5, 2026</chron></span> /PRNewswire/ - <span value="TorontoVE:ZYUS" idsrc="xmltag.org" >ZYUS Life Sciences Corporation</span> (the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, announced today that the United States Patent and Trademark Office ("USPTO") has issued <location value="LC/us" idsrc="xmltag.org" >U.S.</location> Patent No. 12,616,704, entitled CANNABICHROMENE FORMULATION FOR PAIN MANAGEMENT on today's date.  The patent, held by ZYUS' wholly owned subsidiary, <span>ZYUS Life Sciences http://www.streetinsider.com/PRNewswire/ZYUS+Life+Sciences+Expands+U.S.+Patent+Portfolio+with+Second+Pain+Management+Patent/26436802.html Tue, 05 May 2026 18:00:00 -0400 A.06822034 O.02548881 O.20026344 ZYUS http://www.streetinsider.com/FDA/ZYUS+reports+early+data+from+cancer+pain+drug+trial/25824444.html <p>ZYUS Life Sciences Corporation (TSXV: ZYUS) announced preliminary results from its Phase 2a UTOPIA-1 trial evaluating Trichomylin softgel capsules in patients with moderate to severe cancer-related pain.</p> <p>The preliminary data is based on the first 25% of enrolled patients who completed treatment in the single-arm, proof-of-concept study. According to the company, early results showed reductions in average daily pain, pain interference, and pain severity. The trial also recorded reductions in opioid dosing for breakthrough pain.</p> <p>The company reported no serious adverse events related to Trichomylin softgel capsules. Most adverse reactions were described as mild and occurred during dose titration, consistent with the http://www.streetinsider.com/FDA/ZYUS+reports+early+data+from+cancer+pain+drug+trial/25824444.html Thu, 08 Jan 2026 09:24:06 -0400 O.02548881 ZYUS http://www.streetinsider.com/FDA/ZYUS+reports+early+data+from+cancer+pain+drug+trial/25824444.html <p>ZYUS Life Sciences Corporation (TSXV: ZYUS) announced preliminary results from its Phase 2a UTOPIA-1 trial evaluating Trichomylin softgel capsules in patients with moderate to severe cancer-related pain.</p> <p>The preliminary data is based on the first 25% of enrolled patients who completed treatment in the single-arm, proof-of-concept study. According to the company, early results showed reductions in average daily pain, pain interference, and pain severity. The trial also recorded reductions in opioid dosing for breakthrough pain.</p> <p>The company reported no serious adverse events related to Trichomylin softgel capsules. Most adverse reactions were described as mild and occurred during dose titration, consistent with the http://www.streetinsider.com/FDA/ZYUS+reports+early+data+from+cancer+pain+drug+trial/25824444.html Thu, 08 Jan 2026 09:24:06 -0400 O.02548881 ZYUS http://www.streetinsider.com/Press+Releases/ZYUS+Life+Sciences+Reports+Preliminary+Results+from+Ongoing+Phase+2a+UTOPIA-1+Trial+Evaluating+Novel+Non-Opioid+Pain+Drug/25824443.html <div class="xn-content"> <p class="prntac"><i>Early Data Suggests a Trend Toward Improvement in Pain Efficacy</i></p><p><span class="legendSpanClass"><location value="LU/ca.sk.sasoon" idsrc="xmltag.org" >SASKATOON, SK</location></span>, <span class="legendSpanClass"><chron>Jan. 8, 2026</chron></span> /PRNewswire/ - ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, today announced favourable preliminary results from its ongoing Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) trial evaluating Trichomylin® softgel capsules in patients experiencing moderate to severe cancer-related pain.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/ZYUS+Life+Sciences+Reports+Preliminary+Results+from+Ongoing+Phase+2a+UTOPIA-1+Trial+Evaluating+Novel+Non-Opioid+Pain+Drug/25824443.html Thu, 08 Jan 2026 09:23:00 -0400 O.02548881 ZYUS http://www.streetinsider.com/PRNewswire/ZYUS+Life+Sciences+Reports+Preliminary+Results+from+Ongoing+Phase+2a+UTOPIA-1+Trial+Evaluating+Novel+Non-Opioid+Pain+Drug/25824443.html <div class="xn-content"> <p class="prntac"><i>Early Data Suggests a Trend Toward Improvement in Pain Efficacy</i></p><p><span class="legendSpanClass"><location value="LU/ca.sk.sasoon" idsrc="xmltag.org" >SASKATOON, SK</location></span>, <span class="legendSpanClass"><chron>Jan. 8, 2026</chron></span> /PRNewswire/ - ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, today announced favourable preliminary results from its ongoing Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) trial evaluating Trichomylin® softgel capsules in patients experiencing moderate to severe cancer-related pain.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/ZYUS+Life+Sciences+Reports+Preliminary+Results+from+Ongoing+Phase+2a+UTOPIA-1+Trial+Evaluating+Novel+Non-Opioid+Pain+Drug/25824443.html Thu, 08 Jan 2026 09:23:00 -0400 O.02548881 ZYUS http://www.streetinsider.com/Press+Releases/ZYUS+Life+Sciences+Reports+Preliminary+Results+from+Ongoing+Phase+2a+UTOPIA-1+Trial+Evaluating+Novel+Non-Opioid+Pain+Drug/25824443.html <div class="xn-content"> <p class="prntac"><i>Early Data Suggests a Trend Toward Improvement in Pain Efficacy</i></p><p><span class="legendSpanClass"><location value="LU/ca.sk.sasoon" idsrc="xmltag.org" >SASKATOON, SK</location></span>, <span class="legendSpanClass"><chron>Jan. 8, 2026</chron></span> /PRNewswire/ - ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, today announced favourable preliminary results from its ongoing Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) trial evaluating Trichomylin® softgel capsules in patients experiencing moderate to severe cancer-related pain.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/ZYUS+Life+Sciences+Reports+Preliminary+Results+from+Ongoing+Phase+2a+UTOPIA-1+Trial+Evaluating+Novel+Non-Opioid+Pain+Drug/25824443.html Thu, 08 Jan 2026 09:23:00 -0400 O.02548881 ZYUS http://www.streetinsider.com/PRNewswire/ZYUS+Life+Sciences+Reports+Preliminary+Results+from+Ongoing+Phase+2a+UTOPIA-1+Trial+Evaluating+Novel+Non-Opioid+Pain+Drug/25824443.html <div class="xn-content"> <p class="prntac"><i>Early Data Suggests a Trend Toward Improvement in Pain Efficacy</i></p><p><span class="legendSpanClass"><location value="LU/ca.sk.sasoon" idsrc="xmltag.org" >SASKATOON, SK</location></span>, <span class="legendSpanClass"><chron>Jan. 8, 2026</chron></span> /PRNewswire/ - ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, today announced favourable preliminary results from its ongoing Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) trial evaluating Trichomylin® softgel capsules in patients experiencing moderate to severe cancer-related pain.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/ZYUS+Life+Sciences+Reports+Preliminary+Results+from+Ongoing+Phase+2a+UTOPIA-1+Trial+Evaluating+Novel+Non-Opioid+Pain+Drug/25824443.html Thu, 08 Jan 2026 09:23:00 -0400 O.02548881 ZYUS http://www.streetinsider.com/FDA/ZYUS+Life+Sciences+enrolls+first+patient+in+cancer+pain+trial/25249416.html <p>ZYUS Life Sciences Corporation (TSXV: ZYUS) has activated its first clinical site and enrolled the first patient in its Phase 2a UTOPIA-1 cancer pain trial, according to a company statement released August 26.</p> <p>The Centre Hospitalier de l'Université de Montréal serves as the initial clinical site for the single-arm, proof-of-concept study. The trial is designed to investigate the safety and preliminary analgesic efficacy of Trichomylin softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain.</p> <p>UTOPIA-1 stands for Unique Treatment of Oncology Pain in Advanced Cancer. The hospital continues to actively recruit additional patients for the study.</p> <p>"Activating our first http://www.streetinsider.com/FDA/ZYUS+Life+Sciences+enrolls+first+patient+in+cancer+pain+trial/25249416.html Tue, 26 Aug 2025 07:00:32 -0400 O.02548881 ZYUS http://www.streetinsider.com/FDA/ZYUS+Life+Sciences+enrolls+first+patient+in+cancer+pain+trial/25249416.html <p>ZYUS Life Sciences Corporation (TSXV: ZYUS) has activated its first clinical site and enrolled the first patient in its Phase 2a UTOPIA-1 cancer pain trial, according to a company statement released August 26.</p> <p>The Centre Hospitalier de l'Université de Montréal serves as the initial clinical site for the single-arm, proof-of-concept study. The trial is designed to investigate the safety and preliminary analgesic efficacy of Trichomylin softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain.</p> <p>UTOPIA-1 stands for Unique Treatment of Oncology Pain in Advanced Cancer. The hospital continues to actively recruit additional patients for the study.</p> <p>"Activating our first http://www.streetinsider.com/FDA/ZYUS+Life+Sciences+enrolls+first+patient+in+cancer+pain+trial/25249416.html Tue, 26 Aug 2025 07:00:32 -0400 O.02548881 ZYUS http://www.streetinsider.com/Press+Releases/ZYUS+Life+Sciences+Activates+First+Clinical+Site+and+Enrolls+First+Patient+in+Phase+2a+UTOPIA-1+Cancer+Pain+Trial/25249409.html <div class="xn-content"> <p class="prntac"><i>Phase 2a trial designed to investigate the safety and preliminary analgesic efficacy of Trichomylin® softgel capsules </i></p> <p><span class="legendSpanClass"><location value="LU/ca.sk.sasoon" idsrc="xmltag.org" >SASKATOON, SK</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2025</chron></span> /PRNewswire/ - ZYUS Life Sciences Corporation (the &quot;Company&quot;) (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, today announced the activation of the Centre Hospitalier de l&#39;Université de <location value="LU/ca.qc.montrl" idsrc="xmltag.org" >Montréal</location> (&quot;CHUM&quot;) as first clinical site in its Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) clinical trial.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/ZYUS+Life+Sciences+Activates+First+Clinical+Site+and+Enrolls+First+Patient+in+Phase+2a+UTOPIA-1+Cancer+Pain+Trial/25249409.html Tue, 26 Aug 2025 07:00:00 -0400 O.02548881 ZYUS http://www.streetinsider.com/PRNewswire/ZYUS+Life+Sciences+Activates+First+Clinical+Site+and+Enrolls+First+Patient+in+Phase+2a+UTOPIA-1+Cancer+Pain+Trial/25249409.html <div class="xn-content"> <p class="prntac"><i>Phase 2a trial designed to investigate the safety and preliminary analgesic efficacy of Trichomylin® softgel capsules </i></p> <p><span class="legendSpanClass"><location value="LU/ca.sk.sasoon" idsrc="xmltag.org" >SASKATOON, SK</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2025</chron></span> /PRNewswire/ - ZYUS Life Sciences Corporation (the &quot;Company&quot;) (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, today announced the activation of the Centre Hospitalier de l&#39;Université de <location value="LU/ca.qc.montrl" idsrc="xmltag.org" >Montréal</location> (&quot;CHUM&quot;) as first clinical site in its Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) clinical trial.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/ZYUS+Life+Sciences+Activates+First+Clinical+Site+and+Enrolls+First+Patient+in+Phase+2a+UTOPIA-1+Cancer+Pain+Trial/25249409.html Tue, 26 Aug 2025 07:00:00 -0400 O.02548881 ZYUS http://www.streetinsider.com/Press+Releases/ZYUS+Life+Sciences+Activates+First+Clinical+Site+and+Enrolls+First+Patient+in+Phase+2a+UTOPIA-1+Cancer+Pain+Trial/25249409.html <div class="xn-content"> <p class="prntac"><i>Phase 2a trial designed to investigate the safety and preliminary analgesic efficacy of Trichomylin® softgel capsules </i></p> <p><span class="legendSpanClass"><location value="LU/ca.sk.sasoon" idsrc="xmltag.org" >SASKATOON, SK</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2025</chron></span> /PRNewswire/ - ZYUS Life Sciences Corporation (the &quot;Company&quot;) (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, today announced the activation of the Centre Hospitalier de l&#39;Université de <location value="LU/ca.qc.montrl" idsrc="xmltag.org" >Montréal</location> (&quot;CHUM&quot;) as first clinical site in its Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) clinical trial.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/ZYUS+Life+Sciences+Activates+First+Clinical+Site+and+Enrolls+First+Patient+in+Phase+2a+UTOPIA-1+Cancer+Pain+Trial/25249409.html Tue, 26 Aug 2025 07:00:00 -0400 O.02548881 ZYUS http://www.streetinsider.com/PRNewswire/ZYUS+Life+Sciences+Activates+First+Clinical+Site+and+Enrolls+First+Patient+in+Phase+2a+UTOPIA-1+Cancer+Pain+Trial/25249409.html <div class="xn-content"> <p class="prntac"><i>Phase 2a trial designed to investigate the safety and preliminary analgesic efficacy of Trichomylin® softgel capsules </i></p> <p><span class="legendSpanClass"><location value="LU/ca.sk.sasoon" idsrc="xmltag.org" >SASKATOON, SK</location></span>, <span class="legendSpanClass"><chron>Aug. 26, 2025</chron></span> /PRNewswire/ - ZYUS Life Sciences Corporation (the &quot;Company&quot;) (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, today announced the activation of the Centre Hospitalier de l&#39;Université de <location value="LU/ca.qc.montrl" idsrc="xmltag.org" >Montréal</location> (&quot;CHUM&quot;) as first clinical site in its Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) clinical trial.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/ZYUS+Life+Sciences+Activates+First+Clinical+Site+and+Enrolls+First+Patient+in+Phase+2a+UTOPIA-1+Cancer+Pain+Trial/25249409.html Tue, 26 Aug 2025 07:00:00 -0400 O.02548881 ZYUS http://www.streetinsider.com/SEC+Filings/Form++D++++++++++Zyus+Life+Sciences+Corp++++++++++++++/25191412.html si-local-file:///var/storage/secattach/20250813/25191412.html http://www.streetinsider.com/SEC+Filings/Form++D++++++++++Zyus+Life+Sciences+Corp++++++++++++++/25191412.html Wed, 13 Aug 2025 06:04:00 -0400 O.02548881 ZLSCF ZYUS http://www.streetinsider.com/SEC+Filings/Form++D++++++++++Zyus+Life+Sciences+Corp++++++++++++++/25191412.html si-local-file:///var/storage/secattach/20250813/25191412.html http://www.streetinsider.com/SEC+Filings/Form++D++++++++++Zyus+Life+Sciences+Corp++++++++++++++/25191412.html Wed, 13 Aug 2025 06:04:00 -0400 O.02548881 ZLSCF ZYUS